一、复牌、停牌 1、江丰电子：拟收购凯德石英15.6424%股份，股票复牌。 2、天汽模：正在筹划通过发行股份及支付现金的方式购买东实汽车科技集团股权并募集配套资金，股 票停牌。 2、锐新科技：拟发行股份及支付现金购买资产并募集配套资金，股票停牌。 二、定增 国轩高科：拟定增募资不超过50亿元，用于年产20GWh动力电池项目等。 三、增持 孚日股份：安信投资及其一致行动人拟增持300万股-500万股 四、对外投资、日常经营 1、融发核电：全资子公司中标1.01亿元中广核工程公司项目。 2、复星医药：控股子公司与Eisai签订许可协议。 3、健麾信息：拟7371万元收购AI应用公司博科国信38%股权。 4、广生堂：乙肝治疗一类创新药奈瑞可韦GST-HG141完成III期临床试验受试者入组。 5、*ST张股：公司及子公司重整计划执行完毕。 6、立讯精密：拟适度开展外汇衍生品交易业务不超过一年，任意时点累计折合等值不超过49亿美元。 7、东南网架：联合中标9.94亿元EPC项目。 五、业绩变动 1、英集芯：2025年净利润1.77亿元，同比增长42.81%；公司产品在电池管理、PMU、新能源、工业车 规等多个领域实 ...

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Market Overview - The indices experienced fluctuations in the afternoon, with declines narrowing. The Shanghai Composite Index reported at 4078.82 points, down 0.57%, while the Shenzhen Component Index was at 13969.10 points, down 1.32%, and the ChiNext Index at 3266.71 points, down 1.35% [1] Sector Performance - The banking sector saw significant gains, with Xiamen Bank hitting the daily limit and reaching a new high since June 2021 [1] - The innovative drug sector was notably active, with Guangsheng Tang rising over 10% [1] - The securities sector also experienced a surge, with Hualin Securities hitting the daily limit and other companies like Huaxin Securities, Huatai Securities, and Dongfang Caifu following suit [1] - The tourism and hotel sector showed strength, with Sanxia Tourism reaching the daily limit [1] - Conversely, the precious metals sector faced ongoing adjustments, with Hunan Gold and Hunan Silver hitting the daily limit down [1] - The afternoon saw weakness in the electric grid equipment stocks, with Sifang Co. hitting the daily limit down [1] Stock Movement - Overall, the market saw more stocks declining than rising, with over 3500 stocks down [1] - The beauty care, film and television, and banking sectors led in gains, while BC batteries, photovoltaic equipment, and precious metals sectors led in losses [1]

2月5日早盘，创新药概念股拉升，广生堂涨超13%，方盛制药、舒泰神、通化东宝、翰宇药业、盘龙药 业等涨幅居前。 ...

国机重装：2025年度净利润同比增长10.89% 利亚德：拟不超1亿元投资产业基金，后者将定向投资商业航天（核心股）领域的非上市公司 【经营合作】 【增持回购】 长安汽车：拟以10亿元-20亿元回购公司股份 【业绩】 【重要事项】 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 盛新锂能：全资子公司盛屯锂业拟12.6亿元收购惠绒矿业13.93%股权 广东建工：联合体中标15.24亿元年产2GWh三维固态锂电池（核心股）智能制造生产基地项目 中船防务：签订16艘支线集装箱船建造合同，金额7.36亿美元至8.96亿美元 中文在线：拟与腾讯计算机就动画微短剧授权合作事宜达成合作 东华科技：与青海东台吉乃尔锂资源股份有限公司签订战略合作框架协议 上海医药（核心股）：拟不低于10.23亿元公开挂牌转让中美施贵宝30%股权 中船防务：签订16艘支线集装箱船建造合同 金额7.36亿美元至8.96亿美元 银邦股份：收到Holtec公司约2.8亿元销售订单 斯莱克：控股子公司获韩国电池客户项目定点 惠博普：签订约15.96亿元Naft Khana油田复产项目合同 北新路桥：联合体中标11.45亿元工程项目 康恩贝 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 福建广生堂药业股份有限公司（以下简称"公司"）创新药控股子公司福建广生中霖生物科技有限公司的 在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计 入组578例。 GST-HG141用于慢性乙型肝炎（CHB）抗病毒药物应答不佳患者联合治疗（add-on）的随机、双盲、安 慰剂对照、多中心III期临床试验，主要目的是在经过抗病毒药物治疗的CHB应答不佳患者中评估GST- HG141治疗的有效性和安全性，联合组长单位为树兰（杭州）医院和北京大学第一医院。2026年1月， GST-HG141的III期临床及拓展研究入选新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临 床治愈联合治疗新方案研究"项目课题三，后期拓展研究将进一步评价GST-HG141长期用药后对于 cccDNA的潜在耗竭作用，并续贯联合口服表面抗原抑制剂 GST-HG131等的临床治愈有效性，是凸显重 要临床价值的前瞻性研究。 奈瑞可韦GST-HG14 ...

北京商报讯（记者 丁宁）2月4日晚间，广生堂（300436）发布公告称，公司创新药控股子公司福建广 生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日 完成全部受试者入组，合计入组578例。 公告显示，奈瑞可韦GST-HG141是新型乙肝核心蛋白/核衣壳调节剂，属于全新机制的在研抗乙肝病毒 的一类创新药。迄今为止，全球范围内尚无同类产品上市，属潜在FIC（First in class）项目。 ...

Group 1 - Sileck's subsidiary received a project designation letter from a South Korean battery customer, expected to supply approximately 360 million cylindrical battery shells from 2027 to 2031 [1] - Fuguang Co.'s major shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 481.68 million shares [2] - Beixin Road and Bridge's consortium won a contract for a project worth 1.145 billion yuan, with two segments valued at 223.1 million yuan and 921.5 million yuan respectively [3] Group 2 - Jianyou Co.'s subsidiary received FDA approval for sodium selenite injection, aimed at providing selenium for parenteral nutrition in adults and pediatric patients [4] - China Galaxy received approval to publicly issue subordinated bonds totaling up to 20 billion yuan [6] - Changjiang Electric Power announced a cash dividend of 0.21 yuan per share, totaling 5.138 billion yuan [7] Group 3 - Zhongjin Company received approval to publicly issue corporate bonds totaling up to 20 billion yuan [8] - Daon Co. received a decision from the State Administration for Market Regulation not to conduct further antitrust review on its acquisition of Ningbo Aisikai Synthetic Rubber Co. [10] - Palm Co. won a project worth approximately 228 million yuan, which is expected to account for 7.44% of its audited revenue for 2024 [11] Group 4 - Kang En Bei's subsidiary received approval for clinical trials of TFA003 tablets for diabetic nephropathy [13] - Xinmai Medical's subsidiary obtained a medical device registration certificate for polyvinyl alcohol embolization microspheres [14] - Guangsheng Tang's innovative hepatitis B drug completed the enrollment of 578 participants in its Phase III clinical trial [15] Group 5 - Pianzaihuang's controlling shareholder received a loan commitment for up to 450 million yuan to support share buybacks [16] - Liya De plans to invest up to 100 million yuan in an industry fund focused on commercial aerospace [17] - Zhongwen Online plans to collaborate with Tencent on animation micro-short drama licensing, with an expected cooperation amount of 23.2 million yuan [19] Group 6 - Yungsheng Technology is planning to acquire control of Fengrui Fluorine Industry, with its stock continuing to be suspended [22] - Yinbang Co. received a sales order from HOLTEC ASIA for approximately 280 million yuan, expected to positively impact its operations in 2026 and 2027 [23] - Pailin Bio's subsidiary received a drug registration acceptance notice for human coagulation factor IX [24] Group 7 - Dao Dao Quan plans to apply for soybean oil delivery warehouse qualifications from the Dalian Commodity Exchange [25] - Qizheng Tibetan Medicine's subsidiary received a registration certificate for a traditional Chinese medicine product in Macau [26] - Vili Medical received EU MDR certification for multiple products [27][28] Group 8 - CITIC Bank plans to increase its investment in its wholly-owned subsidiary by 2 billion yuan [29] - Hayao Co. received approval for the consistency evaluation of its injectable drugs [30] - Zhifei Biological's freeze-dried varicella vaccine clinical trial received approval [31] Group 9 - Huibo Pu signed a contract worth 225 million USD for the Naft Khana oilfield recovery project [32] - Zhonggu Logistics plans to invest in the construction of two 6000 TEU container ships, with a total contract amount not exceeding 1.16 billion yuan [33] - Chongqing Beer reported a 10.43% increase in net profit for 2025, with revenue of 14.722 billion yuan [34] Group 10 - Huanxu Electronics reported a 12.16% increase in net profit for 2025, with revenue of 59.195 billion yuan [35] - Chengzhi Co.'s subsidiary successfully completed trial production of a high molecular weight polyethylene project [36] - Guangyang Co. signed a strategic cooperation agreement with Shenzhen Xuanchuang and Huangshan Guangyang [37]

本次GST-HG141完成III期临床试验全部受试者入组后，尚需按照已制定临床方案和要求继续推进临床 试验，并经国家药品审评部门注册审批通过后方可上市。 广生堂（300436）(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙 肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入组578 例。 ...

格隆汇2月4日丨广生堂(300436.SZ)公布，公司创新药控股子公司福建广生中霖生物科技有限公司的在 研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入 组578例。 GST-HG141用于慢性乙型肝炎（CHB）抗病毒药物应答不佳患者联合治疗（add-on）的随机、双盲、安 慰剂对照、多中心III期临床试验，主要目的是在经过抗病毒药物治疗的CHB应答不佳患者中评估GST- HG141治疗的有效性和安全性，联合组长单位为树兰（杭州）医院和北京大学第一医院。2026年1月， GST-HG141的III期临床及拓展研究入选新发突发与重大传染病防控国家科技重大专项"慢性乙型肝炎临 床治愈联合治疗新方案研究"项目课题三，后期拓展研究将进一步评价GST-HG141长期用药后对于 cccDNA的潜在耗竭作用，并续贯联合口服表面抗原抑制剂GST-HG131等的临床治愈有效性，是凸显重 要临床价值的前瞻性研究。 ...